secwatch.observer — SEC 8-K summary
======================================

Issuer:     Akebia Therapeutics, Inc. (AKBA)
CIK:        0001517022
Form:       8-K
Filed at:   2022-11-10T23:59:59+00:00
Accession:  0001193125-22-282578
Event type: regulatory
Sentiment:  negative
Materiality: 0.70
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Akebia gets 180-day extension to May 2023 to regain Nasdaq bid price compliance; transfer to Capital Market
--------------------------------------------------------------------------------

- Received 180-day extension from Nasdaq to regain $1.00 bid price compliance until May 8, 2023.
- Failed to meet initial compliance deadline of November 8, 2022.
- Transfer from Nasdaq Global Market to Nasdaq Capital Market approved, effective November 11, 2022.
- Stock continues trading under symbol AKBA; if not compliant by May 8, 2023, delisting process may begin.
- Company indicated intention to cure deficiency via reverse stock split if necessary.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1517022/000119312522282578/0001193125-22-282578-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1517022/000119312522282578/d744480d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-282578

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer